amiodarone has been researched along with Ataxia in 15 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone is recommended for the cardioversion of atrial fibrillation and prevention of paroxysmal atrial fibrillation in patients with structural heart disease, coronary artery disease or left ventricular dysfunction." | 7.74 | Ataxia caused by amiodarone in older people. ( Hindle, JV; Ibrahim, A; Ramaraj, R, 2008) |
| "Neurologic toxicity is an infrequently reported and under-recognized consequence of amiodarone, symptoms of which may include tremor, peripheral sensorimotor neuropathy, proximal weakness, and ataxia." | 7.73 | Severe ataxia caused by amiodarone. ( Kligfield, P; Krauser, DG; Segal, AZ, 2005) |
| "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs." | 7.66 | Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983) |
| "Amiodarone is an antiarrhythmic drug with a significant adverse effect profile, including neurotoxicity." | 7.01 | Amiodarone-Induced Nystagmus and Ataxia: Case Report and Systematic Review of Case Reports. ( Dumic, I; Kaur, A; Kaur, P; Khaliq, W; Singh, A; Sinha, A, 2023) |
| "Propafenone is an effective antiarrhythmic drug used widely for the treatment of supraventricular and ventricular arrhythmias." | 5.31 | Propafenone-induced ataxia: report of three cases. ( Odeh, M; Oliven, A; Seligmann, H, 2000) |
| " She was recently diagnosed with refractory atrial flutter and was prescribed amiodarone." | 3.79 | Ataxia: a diagnostic perplexity and management dilemma. ( Chaubey, VK; Chhabra, L; Kapila, A, 2013) |
| "A 76-year-old man developed ataxia after taking amiodarone hydrochloride 400 mg orally three times daily for more than two months; the regimen was the intended loading dosage." | 3.75 | Amiodarone-induced neurotoxicity. ( Lugo, AM; Willis, MS, 2009) |
| "Amiodarone is recommended for the cardioversion of atrial fibrillation and prevention of paroxysmal atrial fibrillation in patients with structural heart disease, coronary artery disease or left ventricular dysfunction." | 3.74 | Ataxia caused by amiodarone in older people. ( Hindle, JV; Ibrahim, A; Ramaraj, R, 2008) |
| "Neurologic toxicity is an infrequently reported and under-recognized consequence of amiodarone, symptoms of which may include tremor, peripheral sensorimotor neuropathy, proximal weakness, and ataxia." | 3.73 | Severe ataxia caused by amiodarone. ( Kligfield, P; Krauser, DG; Segal, AZ, 2005) |
| "To assess the incidence of adverse effects associated with long-term amiodarone therapy, we reviewed the records of 217 consecutive patients who were treated for refractory arrhythmia." | 3.67 | Side effects and complications of amiodarone therapy. ( Lown, B; Podrid, PJ; Raeder, EA, 1985) |
| "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs." | 3.66 | Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983) |
| "Amiodarone is an antiarrhythmic drug with a significant adverse effect profile, including neurotoxicity." | 3.01 | Amiodarone-Induced Nystagmus and Ataxia: Case Report and Systematic Review of Case Reports. ( Dumic, I; Kaur, A; Kaur, P; Khaliq, W; Singh, A; Sinha, A, 2023) |
| "Propafenone is an effective antiarrhythmic drug used widely for the treatment of supraventricular and ventricular arrhythmias." | 1.31 | Propafenone-induced ataxia: report of three cases. ( Odeh, M; Oliven, A; Seligmann, H, 2000) |
| "Paraesthesiae, ataxia, vertigo and tremor were the most common (7-9%)." | 1.28 | Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme. ( Coulter, DM; Edwards, IR; Savage, RL, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (26.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Catalano, A | 1 |
| Desaphy, JF | 1 |
| Lentini, G | 1 |
| Carocci, A | 1 |
| Di Mola, A | 1 |
| Bruno, C | 1 |
| Carbonara, R | 1 |
| De Palma, A | 1 |
| Budriesi, R | 1 |
| Ghelardini, C | 1 |
| Perrone, MG | 1 |
| Colabufo, NA | 1 |
| Conte Camerino, D | 1 |
| Franchini, C | 1 |
| Kaur, P | 1 |
| Kaur, A | 1 |
| Sinha, A | 1 |
| Khaliq, W | 1 |
| Dumic, I | 1 |
| Singh, A | 1 |
| Sarrazin, S | 1 |
| Hein, C | 1 |
| Delrieu, J | 1 |
| Crestani, S | 1 |
| Menhour, S | 1 |
| Gilbert-Fontan, E | 1 |
| Abellan van Kan, G | 1 |
| Chaubey, VK | 1 |
| Chhabra, L | 1 |
| Kapila, A | 1 |
| Willis, MS | 1 |
| Lugo, AM | 1 |
| Krauser, DG | 1 |
| Segal, AZ | 1 |
| Kligfield, P | 1 |
| Kashyap, AS | 1 |
| Anand, KP | 1 |
| Kashyap, S | 1 |
| Hindle, JV | 1 |
| Ibrahim, A | 1 |
| Ramaraj, R | 1 |
| Gore, JM | 1 |
| Haffajee, CI | 1 |
| Alpert, JS | 1 |
| Charness, ME | 1 |
| Morady, F | 2 |
| Scheinman, MM | 2 |
| Sauve, MJ | 1 |
| Malone, P | 1 |
| Shen, EN | 1 |
| Schwartz, AB | 1 |
| Bhandari, A | 1 |
| Keung, E | 1 |
| Sung, RJ | 1 |
| Onofrj, M | 1 |
| Thomas, A | 1 |
| Odeh, M | 1 |
| Seligmann, H | 1 |
| Oliven, A | 1 |
| Coulter, DM | 1 |
| Edwards, IR | 1 |
| Savage, RL | 1 |
| Raeder, EA | 1 |
| Podrid, PJ | 1 |
| Lown, B | 1 |
2 reviews available for amiodarone and Ataxia
| Article | Year |
|---|---|
Amiodarone-Induced Nystagmus and Ataxia: Case Report and Systematic Review of Case Reports.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Dizziness; Drug- | 2023 |
Amiodarone-induced Ataxia: A Case Report of Severe Cerebellar Dysfunction and Review of Literature.
Topics: Aged, 80 and over; Amiodarone; Ataxia; Cerebellar Diseases; Humans; Male | 2021 |
13 other studies available for amiodarone and Ataxia
| Article | Year |
|---|---|
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
Topics: Animals; Anti-Arrhythmia Agents; Aorta; Ataxia; ATP Binding Cassette Transporter, Subfamily B, Membe | 2012 |
Ataxia: a diagnostic perplexity and management dilemma.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Flutter; Diagnosis, Differential; Female; F | 2013 |
Amiodarone-induced neurotoxicity.
Topics: Aged; Amiodarone; Ataxia; Humans; Male; Neurotoxicity Syndromes; Postural Balance | 2009 |
Severe ataxia caused by amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Cardiomyopathy, | 2005 |
Severe ataxia caused by amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Cardiomyopathy, | 2006 |
Ataxia caused by amiodarone in older people.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Dose-Response Re | 2008 |
Interaction of amiodarone and diphenylhydantoin.
Topics: Aged; Amiodarone; Ataxia; Benzofurans; Drug Interactions; Humans; Male; Myocardial Infarction; Pheny | 1984 |
Frequent neurologic toxicity associated with amiodarone therapy.
Topics: Amiodarone; Ataxia; Benzofurans; Female; Humans; Male; Middle Aged; Nervous System Diseases; Tremor | 1984 |
Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.
Topics: Aged; Amiodarone; Anorexia; Ataxia; Benzofurans; Female; Heart Arrest; Humans; Lung Diseases; Male; | 1983 |
Acetazolamide-responsive periodic ataxia induced by amiodarone.
Topics: Acetazolamide; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticonvulsants; Ataxia; Dysarthria; Humans | 1999 |
Propafenone-induced ataxia: report of three cases.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Brain; Fem | 2000 |
Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme.
Topics: Amiodarone; Ataxia; Humans; Nervous System Diseases; New Zealand; Paresthesia; Product Surveillance, | 1990 |
Side effects and complications of amiodarone therapy.
Topics: Amiodarone; Arrhythmias, Cardiac; Ataxia; Benzofurans; Drug Eruptions; Drug Interactions; Female; Ga | 1985 |